Intravenous tirofiban before endovascular thrombectomy

Phase 3Small molecule

GGeneral Hospital of Shenyang Military Region

Intravenous tirofiban before endovascular thrombectomy is one of 29 small molecule programs targeting Ischemic stroke. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ischemic StrokeActive, not recruiting

Ischemic StrokePhase 3

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Intravenous tirofiban before endovascular thrombectomy

GGeneral Hospital of Shenyang Military Region

Phase 3

1 2

Repatha

Amgen

Preclinical

2 3

Levaquin

WWim Janssens

Preclinical

3 4

Tylenol

KKenvue Brands

Preclinical

1 5

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 6

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 7

Statins

Sanofi

Preclinical

1 8

Urokinase

Mmedac GmbH

Preclinical

3 9

Drug Therapy

MMassachusetts General Hospital

Preclinical

1 10

Ginkgo Biloba Extract

NNational Center for Complementary and Integrative Health (NCCIH)

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Ischemic Stroke

NCT07135089

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban

Recruiting·GGeneral Hospital of Shenyang Military Region·Phase 3·NCT07135089·870 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intravenous tirofiban before endovascular thrombectomy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intravenous tirofiban before endovascular thrombectomy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intravenous tirofiban before endovascular thrombectomy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — General Hospital of Shenyang Military Region company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGeneral Hospital of Shenyang Military Region

Intravenous tirofiban before endovascular thrombectomy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Ischemic stroke1 trial

References

Drug Info

Quick Facts

Related News